Profile of ciclesonide for the maintenance treatment of asthma
| Autor: | Effie Singas, Jill P Karpel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Budesonide
medicine.drug_class Ciclesonide Review Pharmacology Fluticasone propionate Pulmonary function testing maintenance corticosteroids chemistry.chemical_compound medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Adverse effect Asthma Chemical Health and Safety business.industry Inhaler General Medicine asthma medicine.disease chemistry Corticosteroid ciclesonide business Safety Research medicine.drug |
| Zdroj: | Therapeutics and Clinical Risk Management |
| ISSN: | 1178-203X 1176-6336 |
| Popis: | Ciclesonide is a nonhalogenated synthetic inhaled corticosteroid (ICS) that has been approved by the US Food and Drug Administration for the treatment of all severities of persistent asthma. It is available as a hydrofluroalkane pressurized metered-dose inhaler in two strengths, 80 mcg/activation and 160 mcg/activation, with the recommenced dosage being two inhalations twice-daily. It is a prodrug that is converted in the lung to its active form, which possesses 100-fold greater glucocorticoid-receptor-binding affinity than the parent compound. Its relative receptor affinity is similar to budesonide. In clinical studies, ciclesonide was effective in improving pulmonary function, reducing asthma symptoms, and reducing or eliminating the need for oral corticosteroids (OCSs). Patients with severe asthma dependent on OCSs and high doses of ICSs were able to achieve greater asthma control and reduce or even eliminate the use of OCSs when switched to ciclesonide. In comparison with fluticasone propionate and budesonide, ciclesonide was demonstrated to be at least as effective in maintaining pulmonary function and asthma control. In clinical trials, ciclesonide was well tolerated, with the majority of adverse events considered mild or moderate in intensity. It had low systemic bioavailability and no clinically significant hypothalamic–pituitary–adrenal axis suppression at therapeutic doses. Its safety profile establishes ciclesonide as an important addition to the currently available ICSs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|